BioNTech SE announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for BNT111, an investigational cancer immunotherapy for the potential treatment of advanced melanoma. BNT111 is the lead product candidate from BioNTech’s fully owned FixVac platform that utilizes a fixed combination of mRNA-encoded, tumor-associated antigens aiming to trigger a strong and precise immune response against cancer.
- Read more about BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/biontech-receives-fda-fast-track-designation-for-its-fixvac-candidate-bnt111-in-advanced-melanoma
No comments:
Post a Comment